leisure time -WSS

leisure time

author：focus 2025-10-01 21:33:17 - browse：15384

Without question, the new federal law banning surprise billing is achieving its goal of protecting patients from enormous medical bills. But in doing so, the measure, which was initially projected to lower federal spending, appears to be raising costs elsewhere.

The Biden administration’s new progress report on the process for arbitrating disagreements between insurance companies and providers, which covers the first six months of 2023, shows that in over 80% of payment disputes, the arbiter settled on an amount that was more than the median in-network rate for that service. In other words, insurers were ordered to pay more to an out-of-network provider than they’d pay to a contracted one. Not only that, the sheer volume of disputes means the three federal agencies that run the program are devoting much more time to it than expected.

“It raises concerns for folks that envisioned the arbitration process as helping to moderate costs rather than be a tool these companies can leverage to obtain even higher payments,” said Zachary Baron, the director of Georgetown University’s Health Policy and Law Initiative.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readers discuss the intersection of pregnancy and addiction

focus

WSS

Medical device trials still don't enroll enough women, study finds

My daughter's legacy lives on through her writing, phage therapy

There's no autism epidemic. It's an autism diagnosis epidemic

Roche subsidiary Foundation Medicine opens new headquarters

Teladoc has a new CEO, but challenges remain the same

'Essentially witchcraft:' A former naturopath takes on the field

hotspot

leisure time

entertainment

The high cost of giving birth even with insurance

5 takeaways from STAT's examination of Zynex Medical

Psychedelics group wrestles with new pharma identity

Medical device trials still don't enroll enough women, study finds

Novavax promises a turnaround & Lilly roils the obesity market

Patient advocates debate FDA's accelerated approval process

Activists slam private health insurers over coverage restrictions

Pharma companies must ensure equitable access to obesity drugs

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout LOUD podcast: mifepristone case, GLP

explore

Statins may not be needed by millions of people, study suggests

ALS patient reclaims some autonomy thanks to wearable 'robot'

The system is set up to fail children with medical complexity

Readout LOUD podcast: mifepristone case, GLP

STAT Virtual Event: ASCO Recap, Live!

Teladoc has a new CEO, but challenges remain the same

focus

focus

hotspot

focus